Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hit the mark. Joop van Gerven and Justin Hay of CHDR discuss how carefully chosen biomarkers can easily be incorporated into early phase drug studies, providing guidance for important decisions concerning a drug’s future.
Hit the mark. Joop van Gerven and Justin Hay of CHDR discuss how carefully chosen biomarkers can easily be incorporated into early phase drug studies, providing guidance for important decisions concerning a drug’s future.